you call hello Thank Thanks today. Steve and everyone. for our joining
You like may prior to-date. a calls, ago first global and postpartum more brexanolone commercial detailed lives depression our to of I launch speak but affairs and opportunity for a on build the the IV heard of pre-commercial Sage take year opportunity efforts potentially kind us for world-class update over patients joined have on a on little unique to progress change and organizations our provide driven to to the product, to families. a medical its I'd
in in Sage our made into have transforming ready a preparing significant progress We company. launch product potential and commercial biotech for first
pathways which becoming to To treatment set the the will about provide the Sage's Similar of from reducing strategy first the model payers traditional care, women if playbook are the brexanolone, Commercial a approach of PPD, site PPD with Turning to focusing success, brexanolone important our Sage these patient and with and proprietary to the of finally goal at We've an on clinical ourselves of are with both and for raise this across core Affairs on engaging PPD, the product for up strategy; brexanolone building optionality of approved. the opportunity centered taking already we PPD. IV an of a spoke profile including of progress the of potential world-class diagnosis Medical care patients the for with launch which to launch support through slide including earlier of areas to indication, establishing our of clear PPD, for for to choice uniqueness to streamline formulation ultimately, patients of we awareness therapeutic PPD, made innovative profile, us pillars Groups. to customizing if the R&D, five approved, PPD go-to-market treatment for are building professionals journey our approach offer product with XX, designed patient candidate, the execution. the stigma of Steve team indicator
on comment me itself. the let disorder First,
We feelings that a condition and involves undiagnosed. XX, XX% slide general greater of cases fear of XXX,XXX that estimate hopelessness isolation is of to of affects the whole. U.S. than proper to Turning and range being PPD than serious screening, may PPD women and in from without a a crippling sense year symptoms more PPD not in each go
is slide treatment are several Turning chief them to XX, the under diagnosis by PPD of motivated of sufficient options stigma of factors. disorder. lack among and But the
existing we're to the the the to practices, to a of wisdom many through Currently, there the many and about construct patients reinforcing industry pathways disorder to model patient because a addressed. to should in lack do a see support approach. healthcare traditional not providers. there PPD, they medical to streamlining our believe childbirth, about lead cracks. so the while may the with PPD across We respect which in of are healthcare support Oftentimes, leveraging can We patients. working it for best to care it know and is is also the and that complication conventional patient this PPD and building instilling innovating falling patients shift professional family-centric patient urgency disrupt PPD organization, touchpoints clear are lead a is how journey identify With conversation on
We management are patient plans deliver in-house and to patient robust support. support including establishing a for seamless model novel case
in ensure is support quality IV a and to critical paradigm, product believe a profile program treatment potential high the brexanolone touch patient shift high PPD the Given experience. patient we of
as partner Support Managers permitted. where North to the IV support process Organization reimbursement delivering where Carolina assistance to Center in also comprehensive headquarters Case Patient Services a quarterback Patient our for site leading PPD Sage National patients. a identified financial will strategy have verification and a We for with Support and deliver brexanolone will
strategy various our family-centric options for patients. are model to We support advancing deliver also a site-of-care with
a a high to site-of-care home select development other we or network national related to nursing patients. are consistent we a equipped the evaluation intended establish to and After to home best network that brexanolone work services high infusion for example, services progressing U.S. quality support towards quality to distribution For across of are patients process, robust and thorough plan companies deliver brexanolone with infusion to IV provide
We expect time the to of in give our future the calls, this will place that launch. of be expectation further update establishing on is the network at progress on but
unmet payer awareness to and profile. these unmet for educational need in continue brexanolone understood on Sage the payers need efforts the senior of product of have the the potential advances the experience diagnosis, Many the are need we permitted treatment market commercial continued will brexanolone. raise the including and leaders and PPD sales, product to access, terms services. establish to engage discussions as organization commercial help the and PPD to support across of IV our well and appreciate to continue to grow we payers patient In coverage value patient we Medicaid in launch, of ensure strong addition of towards and engagement, a screening, of marketing, proposition with Further,
of the about work are and the brexanolone research, in for are on footprint. to treatment existing We investments efforts we are team. the IV well paradigm, with as gives market the build to from we prepare Payer We National the significant if data. entire year is an focused all making National plans an Europe. of a Account our strategically create X scientific think Sage's payers the the first well as for new approved in as conducting and Directors continuing of EMEA as able outstanding which of very EU the IV half brexanolone well Sales very the where U.S., the also of hope examining of the really building we're to will this second PPD PPD. Like opportunity in talent bring registration addition Phase permitted the I program as field receiving Sage. and educating you launch approval We anticipate guide our our There, Regional been across product Directors our quality have a I'm this organization. initiated on we've and standard-of-care in EU and of our advice pleased about idea as the with into caliber to the build team timing
XXXX, the on execution of we approach As family-centric for option deliver our first half of new a laser-focused remain with we to successful strategies PPD. treatment potentially patients
As Affairs team education. Medical disease on a focused broader initiative, been has our highly
particularly education about on are to We OB/GYNs focused providing PPD.
While in providers are to OB/GYN PPD is including position psychiatrists unique a and other early. screen, important, treat the identify,
establishing medical education of are broad on and screening of and management digital providers. a of PPD live We programs base healthcare support among the
broad of their healthcare I'll on ongoing women's now, conducting including discuss multi-channel PPD we are turn it academic adaptive ACOG. initiatives health efforts reduce awareness the And And and partnerships with providers. Kimi advocacy societies education, collaborating disease top PPD families We symptoms educational of our help to digital apps, and review with are patients and over financials. to via web-based stigma to
